ArticleNPJ precision oncology2020

Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer.

Ke-Da Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.